Delhi AIIMS has achieved a historic achievement in the field of stroke treatment. AIIMS was the national coordination center and major recruitment site for the GRASSROOT trial, the country's first dedicated Indian clinical trial, in which the state-of-the-art stroke device Supernova Stent was successfully tested.
Dr. Shailesh B., head of the Neuroimaging and Interventional Neuroradiology department of AIIMS and the national principal investigator of this trial. Gaikwad called it a turning point for stroke treatment in India. The results of the trial have been published in the prestigious international journal Journal of Neurointerventional Surgery (JNIS), in which this stent has been declared safe and effective in the treatment of severe stroke patients.
On the basis of GRASSROOT trial, this year the Central Drugs Standard Control Organization (CDSCO) approved Supernova stent for regular use in India. This is the first time that a stroke device has been approved based entirely on Indian clinical trials. This trial conducted in eight major medical centers of the country has given new strength to the Make in India initiative.
Neurology Professor of AIIMS, Dr. Deepti Vibha said that the cooperation of patients and their families is important and said that with this, cheap and fast treatment will be available to millions of people. At the same time, scientists of Gravity Medical Technology called it a proof of India's global level research capability.
Dr. Gaikwad appreciated the contribution of the entire team of AIIMS for this achievement. The Supernova stent has been developed keeping in mind the needs of patients in India, where stroke occurs at a relatively young age. The device has already treated more than 300 patients in South-East Asia and will now be available in India at an affordable price. According to experts, this breakthrough has brought new hope for the approximately 17 lakh Indians who are affected by stroke every year.
